Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Xenon for OCD
NCT02098148Phase 2Withdrawn
- Sponsor
- McLean Hospital
- Start
- Nov 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xenon in obsessive compulsive disorder (OCD) (2 arms), sponsored by McLean Hospital. Primary endpoint: Decrease in OCD Symptoms. Planned start Nov 2013; status: withdrawn.
02
Drugs
xenon
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02098148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098148.